The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s hemato oncology testing market report forecasts the hemato oncology testing market size to grow to $5.24 Billion by 2027, with a CAGR (compound annual growth rate) of more than 13%.

Learn More On The Hemato Oncology Testing Market Report 2023 – https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

Hemato Oncology Testing Market Size Forecast
The global hemato oncology testing market is expected to grow from $2.79 billion in 2022 to $3.16 billion in 2023 at a compound annual growth rate (CAGR) of 13.14%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hemato oncology testing market size is expected to reach $5.24 billion in 2027 at a CAGR of 13.53%.

North America held the largest hemato oncology testing market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Hemato Oncology Testing Market Driver ­– Increase In The Incidence Of Hematologic Cancer
According to the American Cancer Society, a US-based voluntary health organisation dedicated to cancer eradication, leukaemia is expected to affect 59,610 Americans in 2023 and cause 23,710 deaths. Furthermore, new non-Hodgkin lymphoma patients are predicted to afflict 80,550 people in the United States and kill 20,180 people. As a result, the rising occurrence of hematopoietic tumours is driving growth in the hemato oncology market.

Request for A Sample Of The Global Hemato Oncology Testing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10075&type=smp

Key Hemato Oncology Testing Market Trend – Product Innovations
To maintain their market position, major players in the hemato oncology testing market are launching innovative products like as the Sysmex CLIA-validated liquid biopsy test. For example, Sysmex Inostics, a biotechnology company based in the United States, will develop a novel liquid biopsy test for the identification of Minimal Residual Disease (MRD) in Acute Myeloid Leukaemia (AML) in October 2021. The new product makes use of Next Generation Sequencing (NGS) technology that is targeted. The product is unusual in that it is ultra-sensitive and detects even the smallest existence of cancer cells after initial therapy.

Hemato Oncology Testing Market Segment
1) By Product And Services: Assay Kits And Reagents, Services
2) By Cancer Type: Leukemia, Lymphoma, Multiple Myeloma, Other Cancers
3) By Technology: Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Other Technologies
4) By End User: Hospitals, Academic And Research Institutes, Other End Users

Hemato Oncology Testing Market Major Players and Strategies
Major players in the hemato oncology testing market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Icon plc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., Arup Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., Entrogen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc. and Siemens AG.

Merck & Co. Inc., a US-based pharmaceutical business, paid $1.35 billion for Imago BioSciences, Inc. in January 2023. Merck’s goal of investing in its pipeline to increase its footprint in the field of haematology was continued with this acquisition. Imago BioSciences Inc. is a biotechnology firm established in the United States that develops diagnostic and therapeutic products for hemato oncology testing and other blood-related ailments.

The Hemato Oncology Testing Global Market Report 2023 covers regional data on hemato oncology testing market size, hemato oncology testing market trends and drivers, opportunities, strategies, and hemato oncology testing market competitor analysis. The countries covered in the hemato oncology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Hemato oncology testing is a diagnostic test used to detect the existence of symptoms associated with blood diseases and blood malignancies. Anaemia, infection, haemophilia, blood-clotting disorders, and leukaemia are all diagnosed using these assays.

View More Reports Related To The Hemato Oncology Testing Market –
Hematology Diagnostic Devices And Equipment Global Market Report 2023
Hematology Analyzers And Reagents Global Market Report 2023
Oncology Biosimilars Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: